AlphAIAlphAI — Financial news for AI agents
SEC EDGARNOV 21 min read$CRBP

Cormorant Asset Management, LP (Chen Bihua) sold $1.7M of CRBP (indirect holdings)

Cormorant Asset Management, LP sold 425,000 indirectly-held shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $4.10 ($1.74M total) on 2026-10-29. Filed jointly with Cormorant Global Healthcare Master Fund, LP and Chen Bihua.

Original reporting
SEC EDGAR · Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua
Published Nov 2, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRBP
Bearish
medium confidence
Mentioned
$CRBP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRBPBearishLow
01

Why it matters

The disclosed sale may influence short-term trading sentiment.

02

Market read

Insider sale of a small biotech; modest relevance for traders monitoring CRBP.

03

What to watch

No accompanying news on clinical trials or financing that might contextualize the sale.

Relevance 6/10Novelty 6/10Timing: post-market filing

Background

SEC Form 4 filing reports an insider transaction for Corbus Pharmaceuticals.

Company-level read

Ticker impact

$CRBPBearishMedium confidence
Context

Form 4 disclosed Cormorant Asset Management sold 425,000 shares of Corbus Pharmaceuticals for $1.74M, reducing its stake.

Expected impact

likely downward pressure as investors price in the insider sell.

Evidence & confidence

The sale represents a $1.7M divestment by a major holder; such insider sales often lead to modest price declines.

Market effects

Sector

Minimal impact on the broader biotech sector; isolated to Corbus.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • company
    Corbus Pharmaceuticals Holdings, Inc.

    Biotech firm whose shares were sold.

  • institution
    Cormorant Asset Management, LP

    Insider reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRBP insider trading history →

Related articles

SEP 15
$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

finance.biggo.com2 min
SEP 15
$CRBPMedAI 8/10

Obesity drug could have fewer side effects than GLP-1s

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development

foodnavigator.com2 min
SEP 14
$CRBPHighAI 8/10

Why is Corbus Pharmaceuticals stock surging today?

Corbus Pharmaceuticals (CRBP) stock rose 14.4% pre-market after reporting positive Phase 1b trial results for its obesity drug CRB-913, showing significant weight loss and a favorable safety profile. The company plans to present full data in November and initiate a Phase 2 study in 2027. The stock had been near its 52-week low before the announcement.

investing.com2 min
SEP 14
$CRBPHighAI 9/10

Corbus Pharmaceuticals stock rises on obesity drug trial data

Corbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.

investing.com2 min